---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257394"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2026-06-04T20:08:29+00:00"
generated_at: "2026-06-04T20:35:56.270102+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics stockholders elect three Class I directors at 2026 annual meeting

## Summary
- Elected G. Clare Kahn, Ph.D. (49,722,339 for), Adrian Krainer, Ph.D. (36,531,612 for), and Julie Anne Smith (43,500,649 for) as Class I directors.
- Ratified Ernst & Young LLP as independent auditor for FY 2026 with 55,121,163 votes for, 2,036 against.
- Advisory vote on named executive officer compensation passed: 36,436,275 for, 13,565,293 against, 29,415 abstaining.

## SEC filing metadata
- accession: 0001193125-26-257394
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2026-06-04T20:08:29+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/0001193125-26-257394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/d15052d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257394
- JSON: https://secwatch.observer/filing/0001193125-26-257394.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257394.txt

## Key facts
- Shareholder Votes
  Stoke Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Shares For Shares Against Shares Withheld/Abstaining 55,121,163 2,036 51,714
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/0001193125-26-257394-index.htm
- Shareholder Votes
  Stoke Therapeutics, Inc. shareholders approved Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term. at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire upon the earlier of the 2029 annual meeting of stockholders or until such time as their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes G. Clare Kahn, Ph.D. 49,722,339 308,644 5,143,930 Adrian Krainer, Ph.D. 36,531,612 13,499,371 5,143,930 Julie Anne Smith 43,500,649 6,530,334 5,143,930
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/0001193125-26-257394-index.htm
- Shareholder Votes
  Stoke Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026. at the 2026-06-03 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 36,436,275 13,565,293 29,415 5,143,930
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/0001193125-26-257394-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.